These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Epigenetic control of podocyte differentiation: a new target of the renin-angiotensin system in kidney disease. Feliers D Kidney Int; 2015 Oct; 88(4):668-70. PubMed ID: 26422623 [TBL] [Abstract][Full Text] [Related]
4. Comparative effect of direct renin inhibition and AT1R blockade on glomerular filtration barrier injury in the transgenic Ren2 rat. Whaley-Connell A; Nistala R; Habibi J; Hayden MR; Schneider RI; Johnson MS; Tilmon R; Rehmer N; Ferrario CM; Sowers JR Am J Physiol Renal Physiol; 2010 Mar; 298(3):F655-61. PubMed ID: 20007350 [TBL] [Abstract][Full Text] [Related]
5. Podocyte-specific NF-κB inhibition ameliorates proteinuria in adriamycin-induced nephropathy in mice. Yamashita M; Yoshida T; Suzuki S; Homma K; Hayashi M Clin Exp Nephrol; 2017 Feb; 21(1):16-26. PubMed ID: 27089875 [TBL] [Abstract][Full Text] [Related]
6. Effects of angiotensin receptor blocker on phenotypic alterations of podocytes in early diabetic nephropathy. Dai HY; Zheng M; Tang RN; Ni J; Ma KL; Li Q; Liu BC Am J Med Sci; 2011 Mar; 341(3):207-14. PubMed ID: 21326079 [TBL] [Abstract][Full Text] [Related]
7. Effect of angiotensin II type 1 receptor blocker on 12-lipoxygenase activity and slit diaphragm protein expression in type 2 diabetic rat glomeruli. Xu HZ; Wang WN; Zhang YY; Cheng YL; Xu ZG J Nephrol; 2016 Dec; 29(6):775-782. PubMed ID: 27021232 [TBL] [Abstract][Full Text] [Related]
8. Preservations of nephrin and synaptopodin by recombinant hepatocyte growth factor in podocytes for the attenuations of foot process injury and albuminuria in nephritic mice. Kato T; Mizuno S; Nakamura T Nephrology (Carlton); 2011 Mar; 16(3):310-8. PubMed ID: 21342325 [TBL] [Abstract][Full Text] [Related]
9. A molecular mechanism for angiotensin II receptor blocker-mediated slit membrane protection: Angiotensin II increases nephrin endocytosis via AT1-receptor-dependent ERK 1/2 activation. Königshausen E; Zierhut UM; Ruetze M; Rump LC; Sellin L FASEB J; 2024 Sep; 38(17):e70018. PubMed ID: 39212304 [TBL] [Abstract][Full Text] [Related]
10. Hepatocyte growth factor signaling ameliorates podocyte injury and proteinuria. Dai C; Saleem MA; Holzman LB; Mathieson P; Liu Y Kidney Int; 2010 Jun; 77(11):962-73. PubMed ID: 20375988 [TBL] [Abstract][Full Text] [Related]
11. Angiotensin II type 1 receptor blockade ameliorates proteinuria in puromycin aminonucleoside nephropathy by inhibiting the reduction of NEPH1 and nephrin. Takahashi A; Fukusumi Y; Yamazaki M; Kayaba M; Kitazawa Y; Tomita M; Kawachi H J Nephrol; 2014 Dec; 27(6):627-34. PubMed ID: 25298195 [TBL] [Abstract][Full Text] [Related]
13. Angiotensin II induces nephrin dephosphorylation and podocyte injury: role of caveolin-1. Ren Z; Liang W; Chen C; Yang H; Singhal PC; Ding G Cell Signal; 2012 Feb; 24(2):443-450. PubMed ID: 21982880 [TBL] [Abstract][Full Text] [Related]
14. Aliskiren inhibits intracellular angiotensin II levels without affecting (pro)renin receptor signals in human podocytes. Sakoda M; Ichihara A; Kurauchi-Mito A; Narita T; Kinouchi K; Murohashi-Bokuda K; Saleem MA; Nishiyama A; Suzuki F; Itoh H Am J Hypertens; 2010 May; 23(5):575-80. PubMed ID: 20075844 [TBL] [Abstract][Full Text] [Related]
15. Oxidative stress and glomerular filtration barrier injury: role of the renin-angiotensin system in the Ren2 transgenic rat. Whaley-Connell AT; Chowdhury NA; Hayden MR; Stump CS; Habibi J; Wiedmeyer CE; Gallagher PE; Tallant EA; Cooper SA; Link CD; Ferrario C; Sowers JR Am J Physiol Renal Physiol; 2006 Dec; 291(6):F1308-14. PubMed ID: 16788142 [TBL] [Abstract][Full Text] [Related]
16. Combination therapy with telmisartan and oxacalcitriol suppresses the progression of murine adriamycin nephropathy. Jeong KH; Asanuma K; Lydia A; Takagi M; Asao R; Kodama F; Asanuma E; Tomino Y Nephron; 2015; 129(2):143-54. PubMed ID: 25661164 [TBL] [Abstract][Full Text] [Related]
17. Angiotensin II provokes podocyte injury in murine model of HIV-associated nephropathy. Ideura H; Hiromura K; Hiramatsu N; Shigehara T; Takeuchi S; Tomioka M; Sakairi T; Yamashita S; Maeshima A; Kaneko Y; Kuroiwa T; Kopp JB; Nojima Y Am J Physiol Renal Physiol; 2007 Oct; 293(4):F1214-21. PubMed ID: 17652372 [TBL] [Abstract][Full Text] [Related]
18. Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertension. Bonnet F; Cooper ME; Kawachi H; Allen TJ; Boner G; Cao Z Diabetologia; 2001 Jul; 44(7):874-7. PubMed ID: 11508272 [TBL] [Abstract][Full Text] [Related]
19. Fluvastatin prevents podocyte injury in a murine model of HIV-associated nephropathy. Sakurai N; Kuroiwa T; Ikeuchi H; Hiramatsu N; Takeuchi S; Tomioka M; Shigehara T; Maeshima A; Kaneko Y; Hiromura K; Kopp JB; Nojima Y Nephrol Dial Transplant; 2009 Aug; 24(8):2378-83. PubMed ID: 19188342 [TBL] [Abstract][Full Text] [Related]
20. Adjunctive therapy with statins reduces residual albuminuria/proteinuria and provides further renoprotection by downregulating the angiotensin II-AT1 pathway in hypertensive nephropathy. Zhang Z; Li Z; Cao K; Fang D; Wang F; Bi G; Yang J; He Y; Wu J; Wei Y; Song X J Hypertens; 2017 Jul; 35(7):1442-1456. PubMed ID: 28244896 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]